Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Min Fang, MD PhD, Brian G. Till, MD, Mazyar Shadman, MDMPH, Ryan C. Lynch, MD, Andrew J. Cowan, MD, Qian Vicky Wu, PhD, Jenna Voutsinas, MPH, Heather A. Rasmussen, BS, Katie Blue, Chaitra S. Ujjani, MD, Andrei R Shustov, MD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-137328

Published: 2020

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-133763

Published: 2020

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Ajay K. Gopal, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Edus H. Warren, MD PhD, Chaitra S. Ujjani, MD, Mazyar Shadman, MD, Stephen D. Smith, MD, Brian G. Till, MD, Jonathan R. Fromm, MD PhD, Andrei R Shustov, MD, Qian Vicky Wu, PhD, Manoj P. Menon, MD

Blood (2019) 134 (Supplement_1): 5258.

https://doi.org/10.1182/blood-2019-124984

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Adam Greenbaum, MD PhD, Ajay K. Gopal, MD, Jonathan R. Fromm, MD PhD, A McGarry Houghton, MD

Blood (2019) 134 (Supplement_1): 1518.

https://doi.org/10.1182/blood-2019-126217

Published: 2019

Journal Articles

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Colin Godwin, Jonathan R. Fromm, MD PhD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD, Brent Wood, MD PhD, Frederick R. Appelbaum, MD, Rainer F. Storb, MD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2018-99-117745

Published: 2018

Journal Articles

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Solomon A. Graf, MD, Ryan C. Lynch, MD, David G. Coffey, MD, Mazyar Shadman, MD MPH, Sandra Kanan, MSN, ARNP, Edward N. Libby, III, MD, Edus H. Warren, MD PhD, Colin Godwin, Ted Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5326.

https://doi.org/10.1182/blood-2018-99-117572

Published: 2018

Journal Articles

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Stephen D. Smith, MD, Ryan C. Lynch, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Qian V. Wu, PhD, Jenna M. Voutsinas, MSc, Mazyar Shadman, MD MPH, Katie Blue, Andrei R. Shustov, MD, Sandra Kanan, MSN, ARNP, Lauren Low, PA-C, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2018-99-119129

Published: 2018

Journal Articles

Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion

Kirsty Wienand, PhD, Bjoern Chapuy, MDPhD, Chip Stewart, PhD, Andrew Dunford, MS, David Wu, MD PhD, Jaegil Kim, PhD, Atanas Kamburov, PhD, Fathima Zumla Cader, MD PhD MRCP, Matthew D. Ducar, MS, Aaron R. Thorner, PhD, Alexander T Heubeck, BS, Michael J Buonopane, BS, Philippe Armand, MD PhD, Scott J Rodig, MD, Jonathan R. Fromm, MD PhD, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2018) 132 (Supplement 1): 1559.

https://doi.org/10.1182/blood-2018-99-118453

Published: 2018

Journal Articles

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Edward N. Libby, III, MD, Mary Philip, MD PhD, Margaret E. Nartea, Christen N. Heye, ARNP, Sandra L. Kanan, ARNP, Sanaz Behnia, MD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2806.

https://doi.org/10.1182/blood.V130.Suppl_1.2806.2806

Published: 2017

Journal Articles

A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Resistant to Every 3 Week Brentuximab Vedotin

Jacqueline N. Poston, MD, Jonathan R. Fromm, MD PhD, Heather A. Rasmussen, BS, Andrei R. Shustov, MD, Edward N. Libby, III, MD, Stephen D. Smith, MD, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 1528.

https://doi.org/10.1182/blood.V130.Suppl_1.1528.1528

Published: 2017

Journal Articles

Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm

Anna Sherwood, PhD, Harlan Robins, PhD, Jonathan R. Fromm, MD, PhD, Harvey A. Greisman, MD, PhD, Daniel E. Sabath, MD, PhD, Ryan O. Emerson, PhD, Mark J. Rieder, PhD, Brent L. Wood, MD, PhD, David Wu, MD, PhD

Blood (2013) 122 (21): 2614.

https://doi.org/10.1182/blood.V122.21.2614.2614

Published: 2013

Journal Articles

High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia

David Wu, MD, PhD, Anna Sherwood, PhD, Stuart S. Winter, MD, Kimberly Dunsmore, MD, Mignon L Loh, MD, Jonathan R Fromm, MD, PhD, Harvey A Greisman, MD, PhD, Daniel E. Sabath, MD, PhD, Brent L. Wood, MD, PhD, Harlan Robins, PhD

Blood (2011) 118 (21): 2545.

https://doi.org/10.1182/blood.V118.21.2545.2545

Published: 2011

Journal Articles

Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

Jonathan R Fromm, MD, PhD, Julie A. McEarchern, PhD, Dana Kennedy, PharmD, Thomas Anju, Andrei R Shustov, MD, Ajay K Gopal, MD

Blood (2010) 116 (21): 1789.

https://doi.org/10.1182/blood.V116.21.1789.1789

Published: 2010

Journal Articles

I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin’s Lymphoma

Ajay K Gopal, MD, Oliver W. Press, MD, PhD, Jonathan R Fromm, MD, PhD, Shani Wilbur, BS, John M. Pagel, MD, PhD

Blood (2008) 112 (11): 880.

https://doi.org/10.1182/blood.V112.11.880.880

Published: 2008

Journal Articles

Identification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical Hodgkin Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.

Jonathan R. Fromm, MD, PhD, Steven J. Kussick, M.D.,Ph.D., Brent L. Wood, M.D.,Ph.D.

Blood (2006) 108 (11): 2262.

https://doi.org/10.1182/blood.V108.11.2262.2262

Published: 2006

NARROW

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

A Window Study of Ixazomib in Untreated B-NHL

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Resistant to Every 3 Week Brentuximab Vedotin

Detection Of Recurrent/Persistent Disease By T-Cell Receptor Repertoire Profiling In Patients With Mature T-Cell Neoplasm

High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia

Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin’s Lymphoma

Identification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical Hodgkin Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only